Interstitial lung diseases (ILDs)—including idiopathic pulmonary fibrosis (IPF), connective-tissue-disease–associated ILD (CTD-ILD), hypersensitivity pneumonitis (HP), and progressive pulmonary fibrosis (PPF) phenotypes—share a common high-stakes problem: outcomes depend heavily on timely, accurate classification and early initiation of appropriate disease-modifying and supportive care. Across China, the United States, and Europe, the most consistent unmet needs fall into four linked domains: (1) diagnostic delay and misdiagnosis; (2) unequal access to multidisciplinary discussion (MDD/MDT); (3) barriers to initiating antifibrotic and immunosuppressive therapies; and (4) fragmented monitoring and longitudinal care. These gaps translate into avoidable lung function decline, more hospitalizations, worse quality of life, and higher mortality—especially when “mild” disease is diagnosed late or when UIP-pattern ILD is misclassified.
Diagnostic delay and misdiagnosis
Europe (UK and continental Europe)
Real-world registry data from the UK highlight two distinct delays: (a) prolonged time from symptom onset to first specialist encounter, and (b) health-system waiting time from referral to clinic. In the UK IPF Registry (5,052 patients), 36.7% had symptoms for >24 months before their first clinic visit, and 60% reported chest symptoms for >12 months prior to presentation 1. Even after referral, the mean wait from referral to first clinic visit was 13.6 weeks, with specialist ILD centres in England slightly slower than non-specialist centres (13.9 vs 12.8 weeks), and wait times worsened substantially from 2013–2019 before partially improving after 2019 1. The registry authors explicitly emphasized that diagnostic waits are particularly distressing in a disease with “high symptom burden and poor median survival,” and noted evidence that even 6–12 month delays create a survival disadvantage 1.
Continental European administrative data show the downstream consequences of late recognition in non-IPF progressive fibrosing disease: in France’s PROGRESS cohort of PF-ILD (non-IPF) (n=14,413), 95.2% had ≥1 respiratory hospitalization and 34.3% had ICU admission during follow-up; median survival from progression onset was 3.7 years 28. High hospitalization burden (and its costs) is consistent with delayed diagnosis, delayed escalation, or both—especially before antifibrotic approval for PF-ILD in France (mid-2020) 28.
China
China’s multicenter PORTRAY IPF registry (conference abstract reporting baseline of 800 newly diagnosed IPF patients across 33 centers) reported an average 23.99 ± 40.67 months from first symptom onset to first diagnosis 59. Baseline disease severity suggests many patients are not diagnosed at end-stage (median FVC 81% predicted; DLCO 53.7% predicted), but the prolonged time-to-diagnosis implies substantial “silent” progression and lost opportunity to intervene earlier 59. Importantly, the retrieved China-focused evidence did not provide stratification by urban vs rural residence, community vs tertiary pathways, or misdiagnosis rates; that absence is itself an evidence gap in the materials retrieved 5958.
United States
A US Delphi consensus (49 clinicians) converged on a common diagnostic pathway: suspect ILD in chronic cough/dyspnea after common conditions are ruled out; consider pulmonology referral within 1–3 months if not responding; and order HRCT (with explicit technique guidance: thin sections plus expiratory/prone images) when possible 70. The same consensus placed MDD as essential when uncertainty exists or biopsy is considered, with rheumatology involvement when CTD is suspected 70.
However, hospitalization patterns suggest that consistent pathway execution is uneven across the country. From 2016–2020, US severe ILD hospitalizations showed marked state-to-state variability (crude rate 2.1 to 7.9 per 100,000). Only 45.6% of severe ILD hospitalizations ended in routine discharge home, implying substantial post-acute needs 16. Rates correlated with smoking prevalence, environmental toxic exposure risk, and poorer state health rankings—not with density of accredited pulmonary fibrosis centers—indicating that specialized centers alone may not offset broader access and public health inequities 16.
Why delays and misdiagnosis worsen outcomes
While not limited to the three geographies, two recent cohort studies quantify harm from delay and misrecognition of ILD in ways directly relevant to system design. In incident IPF (Denmark, 264 patients), diagnostic delay >1 year was associated with worse progression-free survival (HR 1.70) and markedly shorter time to progression/death (15 vs 36 months). The effect was strongest in patients with mild disease (FVC >80%) at diagnosis (HR 2.43)—precisely the group health systems often deprioritize 69. Longer delay also increased hospitalization rates (all-cause IRR 3.28 in the first year; respiratory IRR 5.80) and worsened quality-of-life scores (SGRQ and CAT) 69. A mixed-methods ILD diagnostic study (Canada) found median symptom-to-diagnosis 12 months, with delays frequently attributed to delayed imaging, delayed referrals, and misdiagnosis; patients commonly perceived under-recognition in primary care 68. Together, these data support a quality imperative: shorten time-to-HRCT, time-to-pulmonology/ILD triage, and time-to-MDD.
MDT/MDD access and implementation
MDD as the Diagnostic Standard: Implementation Gaps Persist
International guidance positions MDD as the reference standard for IPF diagnosis (ATS/ERS/JRS/ALAT) and emphasizes structured evaluation and appropriate biopsy selection when HRCT is not definitive 10. StatPearls summarizes the operational reality: HRCT protocols (≤1.5 mm cuts) and MDD improve diagnostic agreement; surgical lung biopsy carries meaningful risks (reported mortality ~1.7% plus complications), and transbronchial cryobiopsy is only for select patients because risk rises with physiologic impairment and pulmonary hypertension 10.
China has responded with process standardization: a 2023 Chinese expert consensus specifies MDD venue/equipment, pre-review requirements, standardized documentation, and explicit dual goals (diagnosis plus management plan including follow-up and transplant eligibility assessment) [citation:Clinical-Guideline-Search result summarized; citation not numbered there but reflected in web-search citations]64. China also launched a national “ILD Standardized Diagnostic and Therapeutic Center Construction Project” (initiated 2022; 191 units applied across 29 provinces; multiple tiers of recognition), explicitly acknowledging prior fragmentation and non-homogeneity of ILD care 85. National Health Commission standards (2019) for respiratory medical and regional centers specify infrastructure targets (PFT lab capacity, endoscopy, remote consultation platforms, rehabilitation and transplant capability), creating a regulatory scaffold for ILD services 86.
Real-World Impact of MDD and Persistent Access Inequities
A Belgium real-life study (150 ILD cases) illustrates the magnitude of MDD’s impact: 42% had diagnostic revision after MDD; unclassifiable ILD fell sharply (56 to 15); and IPF diagnoses increased five-fold (7 suspected to 35 confirmed) 72. MDD triggered treatment changes/initiation in 54%, increased rehabilitation referrals, enabled trial screening, and generated transplant referrals 72.
Yet a global survey of diagnostic pathways (363 respondents, 64 countries) documented systematic disparities: ILD-specialist centers used more diagnostic tests (median 12 vs 9) and had broader MDT attendance (median 6 vs 3 professions). Crucially, antifibrotic availability was 91% in specialist centers vs 60% in non-specialist centers, and nearly 90% reported virtual MDT capability (with increased regular participation) suggesting tele-MDD can reduce—but not eliminate—geographic inequity 25.
The UIP-Pattern Challenge: Why MDD Matters for Diagnosis and Prognosis
Misclassification is not a theoretical concern. Several sources show that identical HRCT UIP patterns can conceal different underlying diseases with different trajectories and treatment logic:
- Prognosis differs by subtype despite UIP imaging: CTD-ILD with UIP had much slower FVC decline than IPF (e.g., −34.4 mL/year vs −158.4 mL/year in one cohort) and better transplant-free survival (HR 0.50) 3.
- Pathology may not rescue classification: transbronchial cryobiopsy data show that CTD-ILD with UIP, FHP with UIP, and IPF generally cannot be distinguished when UIP is present, reinforcing the need for clinical/exposure/serologic integration in MDD 4.
These findings mean that systems that “shortcut” to labeling UIP-pattern disease as IPF (or fail to involve rheumatology/exposure expertise) risk incorrect prognostic counseling, inappropriate immunosuppression decisions, and missed antigen avoidance strategies for HP.
Treatment initiation barriers
Europe (UK): eligibility thresholds and a two-step referral design can delay treatment
In the UK IPF Registry, antifibrotic prescribing rose from 36.0% (2013) to 55.9% (2023), but barriers persisted 1. In December 2019, among documented reasons for non-prescription, 53% were ineligible due to FVC outside the then NICE 50–80% predicted range, and 37% of patients presented with FVC >80%—a major “early disease” access paradox 1. The registry also described structural delay: antifibrotic prescribing was restricted to 13 specialist ILD centres in England, meaning patients diagnosed in secondary care often required tertiary referral before treatment, creating a two-stage pathway 1.
Continental Europe shows how reimbursement frameworks can formalize functional thresholds. France’s HAS opinion for nintedanib in PF-ILD (Dec 2020) required initiation to be discussed in MDT, and efficacy/safety evidence was limited to patients with FVC ≥45% and DLCO ≥30%, embedding physiologic criteria into access 26. Before PF-ILD approval, antifibrotic use in French PF-ILD (2010–2017) was only 1.6% 28, illustrating how regulatory timing and implementation lag can leave progressive patients exposed to preventable decline and hospitalization.
United States: extreme drug pricing drives affordability gaps even when drugs are approved
A US cost-effectiveness analysis estimated annual drug costs of about $112–113k for pirfenidone/nintedanib, with patient out-of-pocket about $394/month for pirfenidone (plus substantial follow-up care costs, dominated by oxygen costs) 17. At these prices, nintedanib’s ICER was $1.6 million/QALY, far above typical willingness-to-pay thresholds, and threshold pricing implied ~94% price reductions would be needed for cost-effectiveness 17. Real-world adoption consequently remains incomplete (registry ranges cited: 26–70%) 17, consistent with an additional observational US report highlighting high monthly paid amounts and persistent cost-sharing burdens 20.
Separately, US hospitalization data show large cost and discharge variability across states (mean cost $17,155, ranging widely; mean LOS 6.4 days), implying that when outpatient access and early disease management fail, downstream acute-care costs become substantial and uneven 16.
China: reimbursement improvements exist, but rare-disease insurance ceilings and fragmentation remain major constraints
A 2025 policy analysis of China’s rare disease protection framework found outpatient reimbursement ceilings often extremely low relative to rare-disease drug costs: across 31 provincial-level areas, many URRBMI outpatient ceilings were ≤1,000 RMB/year, and UEBMI often ≤6,000 RMB/year, while rare disease medication costs can reach hundreds of thousands to >1 million RMB annually 18. Survey data from a rare-disease organization indicated average annual out-of-pocket expenditure >40,000 RMB, with >80% reporting treatment costs exceeding 80% of household income, meeting catastrophic expenditure definitions 18. This is directly relevant because fibrosing ILDs such as IPF are often framed and financed as rare/high-cost conditions in China’s system 18.
At the same time, web-sourced implementation updates indicate that inclusion of antifibrotics in China’s National Reimbursement Drug List (NRDL) improved utilization, with one report describing a 200% volume spike after nintedanib’s NRDL inclusion 62. The retrieved materials did not provide a national, peer-reviewed quantification of time-to-antifibrotic initiation post-diagnosis or rural/urban differentials, representing an important evidence gap within this search scope.
Immunosuppression and combination therapy
For CTD-ILD, guideline frameworks emphasize balancing immunosuppressive control of inflammation/autoimmunity against antifibrotic therapy for progressive fibrosis. The guideline summary captured in the retrieved guideline tool highlights subtype-specific monitoring intervals and treatment cautions (e.g., long-term steroids discouraged in SSc-ILD; mycophenolate favored for tolerability; biologics like rituximab/tocilizumab in select scenarios) [citation:Clinical-Guideline-Search summary].
Real-world evidence suggests combination approaches can stabilize lung function: a retrospective study of 36 CTD-ILD patients receiving nintedanib plus immunosuppressives reported increased FVC at 6 months (82.8% to 92.3% predicted) and HRCT stabilization/regression in 61.1% 5. However, access inequities (documented in the Asia-Pacific review) show how financing determines whether such regimens are even possible; in some lower-income settings, antifibrotics depend on self-pay or charity pathways 2. While not China/US/Europe-specific, these financing patterns contextualize why cross-regional affordability remains a core determinant of treatment initiation.
Acute exacerbations: a high-mortality setting where access rules may block benefit
A systematic review of antifibrotic initiation during acute exacerbations of ILD (four observational Japanese studies, n=6,321) found nintedanib associated with lower in-hospital mortality (7.1% vs 15.1%) and shorter hospitalization in one large study, plus improved 90-day mortality in another 7. The review noted evidence limitations (observational design, Japan-only), but the signal underscores a practice gap: regulatory or payer rules that withhold antifibrotics in advanced disease or acute presentations may deny benefit precisely when risk is highest 7. A separate review of pirfenidone argues benefit across disease stages and suggests advanced disease should not automatically preclude therapy—though implementation and cost barriers remain 12.
Monitoring and longitudinal management
Europe (UK registry)
In the UK IPF Registry, oxygen needs assessment was performed in 90% of cases, yet only 16% were receiving/prescribed oxygen at presentation despite symptomatic disease burden—suggesting potential delayed initiation or under-recognition of hypoxemia 1. Pulmonary rehabilitation (PR) referral was assessed in 89%, with 57% referred; a substantial fraction were “unsuitable” due to poor mobility, and some declined 1. Palliative care needs assessment occurred in 82%, indicating progress but also variability 1. Clinical trial recruitment remained low at 7.5%, with authors highlighting challenges in a disease with limited options and comorbidity-driven ineligibility—supporting calls for adaptive platform trials 1.
Home monitoring and tele-MDD
Digital/home monitoring is moving from concept to service pilots. A UK protocol (two NHS ILD specialist services) uses weekly home spirometry and oximetry, patient-reported measures, real-time dashboards, and clinician-set alerts (e.g., ≥10% absolute FVC decline, SpO₂ <94%)—with a hypothesis of reducing routine lab PFTs and in-person visits by 50% (results expected end of 2025) 23. The European ILD registry’s ASA-ILD initiative embeds PROMs and home spirometry/oximetry into a smartphone app with AI-supported maneuver quality checks, aiming to detect progression earlier and standardize follow-up 47. ATS guidance has also proposed structured frameworks to assess home monitoring programs across chronic lung disease, including ILD 24.
In the US, quality-improvement infrastructure is increasingly networked: the Pulmonary Fibrosis Foundation Care Center Network reported 86 centers (2025) and described rural outreach efforts including standardized templates for virtual MDD and strategies to improve rural trial recruitment 65. Virtual MDD feasibility is supported by the MILDDER program experience (videoconference MDD plus education): among presented cases with complete data, 50.6% had a new/changed diagnosis, and referring physicians’ diagnostic confidence increased (mean 5.1/10 to 7.5/10) 66. While MILDDER is reported from a Toronto-based expert panel, the model directly addresses the access barrier identified in global surveys—limited MDD expertise in non-specialist centers—and is aligned with the virtual MDT participation trend 2566.
Comorbidity and Whole-Patient Care Gaps in ILD
Several retrieved sources emphasize that outcomes are driven by factors that routine ILD pathways may not systematically address:
- In ILD, dynapenia (low muscle strength) and sarcopenia predicted mortality independently (HR ~2.04 and 1.88) in a prospective cohort (n=98) 6. Yet the study noted no data on whether screening/intervention is routinely implemented—highlighting a modifiable-care gap 6.
- IPF comorbidity burden is extensive: pulmonary hypertension and sleep apnea are prevalent; coronary artery disease risk is elevated; venous thromboembolism risk is increased; GERD is common though treatment benefit is uncertain; osteoporosis, hypothyroidism, anxiety and depression are frequent and prognostically relevant 10.
These data support “longitudinal management” quality indicators that extend beyond PFT/HRCT schedules to include muscle health, cardiopulmonary comorbidity screening, and mental health integration.
Cross-cutting unmet need
Even with better pathways, current antifibrotics slow but do not halt fibrosis. Reviews of vascular remodeling highlight the fibrovascular interface as central to fibrosis initiation/progression, yet therapeutic translation remains limited beyond nintedanib/pirfenidone 11. Precision-medicine reviews describe biomarker-defined endotypes that could improve diagnosis, prognosis, and treatment selection, but state plainly that implementation remains an unmet need due to infrastructure, financial, regulatory, and ethical barriers 9. Meanwhile, the therapeutic pipeline is accelerating: nerandomilast (PDE4B inhibitor) showed phase II efficacy and is in phase III for IPF and PPF, aiming for improved tolerability versus pan-PDE4 inhibition; a 2025 editorial notes a positive phase 3 milestone (FIBRONEER-IPF) as a major advance beyond traditional antifibrotics 821. The gap is now less about “no science” and more about deploying science equitably through scalable diagnostics, trials, and reimbursement models.
“Gap-to-solution” summary table: actionable interventions and measurable indicators
| Domain | Key gaps observed (China vs US vs Europe) | Outcome impact (examples from retrieved sources) | High-impact interventions and measurable indicators |
|---|---|---|---|
| Diagnostic delay & misdiagnosis | China: ~24-month symptom-to-diagnosis in PORTRAY baseline IPF, limited published pathway stratification 59. US: consensus pathway exists but state-level severe ILD hospitalization disparities persist 7016. Europe: UK shows long symptom duration pre-clinic and long referral-to-visit waits 1. | Longer delay worsens progression-free survival, QoL, and increases hospitalizations (IPF evidence) 69. UK authors note survival disadvantage even with 6–12 month delays 1. | Indicators: median symptom-to-HRCT; HRCT-to-pulmonology referral time; symptom-to-MDD-confirmed diagnosis; % diagnosed within 6–12 months. Interventions: primary-care decision support; standardized HRCT ordering language; fast-track ILD triage after abnormal CT 70. |
| MDT/MDD access | Specialist vs non-specialist disparities in MDT composition and antifibrotic access (91% vs 60%) 25. China: national MDD consensus + center-construction program, but variable implementation 6485. | MDD can revise diagnosis in ~42–50%+ and change treatment in ~54% 7266. Prevents UIP-pattern misclassification where prognosis differs by subtype 34. | Indicators: % ILD cases discussed in MDD; time from first specialist visit to MDD; MDT attendance (pulmonology/radiology/pathology/rheumatology). Interventions: tele-MDD (hub-and-spoke); standardized documentation templates; workforce training 2566. |
| Treatment initiation (antifibrotic & immunosuppression) | UK: NICE-era FVC thresholds and tertiary-only prescribing created delays 1. US: extreme prices and cost-sharing limit adoption; drugs not cost-effective at current prices 1720. China: NRDL inclusion improved utilization but rare-disease coverage ceilings and fragmentation can still cause catastrophic OOP burden 6218. | Delayed antifibrotics means more irreversible decline; advanced/acute patients may be denied potentially beneficial therapy. Nintedanib during AE-ILD associated with lower in-hospital mortality in observational data 7. | Indicators: time from diagnosis to antifibrotic start; % eligible patients treated; prior-authorization turnaround time; discontinuation due to cost. Interventions: broaden eligibility aligned to progression risk; shared-care prescribing; transparent reimbursement pathways; combined immunosuppression+antifibrotic protocols for progressive CTD-ILD where appropriate 15. |
| Monitoring & longitudinal care | UK: PR referral 57%, trial recruitment 7.5%, oxygen prescribed in 16% at presentation despite assessment 1. Digital monitoring exists as pilots (UK home monitoring protocol; EU app/registry algorithm) 2347. | Late detection of progression delays escalation and transplant referral; high hospitalization burden in PF-ILD 28. | Indicators: PFT frequency adherence; PRO completion; PR uptake; palliative assessment; time-to-transplant referral triggers. Interventions: home spirometry/oximetry with alerts; standardized monitoring intervals by ILD subtype; integrate comorbidity and sarcopenia screening 236. |
Conclusion
Across China, the US, and Europe, the largest preventable losses in ILD outcomes arise from late/incorrect classification, unequal access to MDD expertise, financial and administrative barriers to disease-modifying therapy, and inconsistent longitudinal care (including supportive therapies and progression detection). The evidence retrieved shows that diagnostic delay is common (UK registry and China registry baseline) 159, harmful (worse progression-free survival, QoL, and higher hospitalization rates when delayed) 69, and exacerbated by system design (multi-step referral and prescribing restrictions; reimbursement thresholds) 11726. MDD is repeatedly shown to change diagnoses and management at high rates and is especially critical where UIP-pattern disease masks divergent biology and prognosis (CTD-ILD vs IPF; HP vs IPF) 7234.
A practical strategy supported by these sources is to set measurable targets for time to HRCT, specialist review, multidisciplinary discussion, and treatment initiation; extend MDT/MDD expertise into community settings through standardized pathways and tele-MDD models; align access criteria with disease behavior and progression risk; and strengthen longitudinal care with pulmonary rehabilitation, oxygen assessment, palliative/supportive care, and structured monitoring so that worsening disease is identified and addressed earlier 123616.